ClinicalTrials.gg
RecruitingNCT07193914PEATUpdated Jan 28, 2026

Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems

An interventional study of ECCCLORE program in PTSD, Addiction and Substance Use Disorders, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in Stress Disorders, Post-Traumatic with a site in France — 33 open to participants now, 33 under way, 3 of them phase 3. Stress Disorders, Post-Traumatic · France.

Planned enrollment
62nd of 81
30 · median 92
Started
2025
with 10 others
No phase
67 of 144
18 open now
Primary completion
2027-03
later than 14 of 32 live
Registered
132nd of 144
by date
Lead sponsor
9 of 144
Centre Hospitalier Universitaire de Nīmes

Among the 144 studies in Stress Disorders, Post-Traumatic with a site in France, this one is the 62nd largest by planned enrollment of the 81 interventional ones that give a count, is one of 11 that started in 2025, is one of 67 with no phase, reaches primary completion later than 14 of the 32 other live ones, and was the 132nd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

33 of the 144 studies in Stress Disorders, Post-Traumatic with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Stress Disorders, Post-Traumatic with a site in France, or all of them as a file.
02

Study summary

Complex posttraumatic stress disorder (cPTSD) is characterized by chronic and pervasive disruptions in emotion regulation, identity, and relationships following prolonged or multiple exposures to trauma. It is frequently found in patients with addiction. Individuals with cPTSD have more severe addiction. In addition, the co-occurrence of these two disorders is often associated with certain transdiagnostic processes such as impulsivity. Indeed, PTSD is linked to a higher impulsivity score, which in turn promotes increased substance use. A second process also associated with trauma and addiction is hostile attribution bias.

Thus, the trauma-addiction comorbidity generates multiple behavioral consequences (aggression, increased substance use, etc.) that impact patients' quality of life and represent an important treatment target. Many authors and clinicians have worked on creating treatment programs targeting both disorders, although group format treatment lacks empirical support. Indeed, even though the Seeking Safety program has been shown to be effective in reducing PTSD symptoms and substance use, there is currently no evidence to suggest its superiority.

The ECCCLORE program is a new 6-month cognitive behavioral therapy protocol initially designed for patients with borderline personality disorder, in whom addictive and traumatic issues are common. It is shorter than the standard dialectical behavioral therapy (DBT) program, which focuses on emotional dysregulation, impulsivity, and the traumatic dimension and lasts at least 1 year. It also integrates techniques from other approaches such as Acceptance and Commitment Therapy (ACT), which promotes the acceptance of internal experiences and engagement in actions consistent with values. It notably contains tools for developing emotional, distress tolerance, and interpersonal skills that could adapt to the difficulties generated by trauma and addiction. The objective of this research is to test the feasibility and acceptability of a 12-week ECCCLORE program adapted for patients with addictive and traumatic problems. The study investigators hypothesize that the implementation of this program will demonstrate satisfactory feasibility and acceptability.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with one or more addictions
  • ASSIST questionnaire score greater than or equal to 11 for alcohol consumption and greater than or equal to 4 for other substances.
  • Diagnosis of PTSD and/or CPTSD assessed using the ITQ scale.
  • Ability to understand, write, and read French
  • The patient must have given their free and
  • The patient must be a member or beneficiary of a health insurance plan

Exclusion criteria

Exclusion Criteria:

  • The subject is participating in an interventional study involving a drug or medical device or a Category 1 study within 3 months prior to inclusion
  • The patient is under safeguard of justice or state guardianship
  • Patients with a psychotic disorder
  • Patients with severe cognitive impairment ( \< 10)
  • Patients experiencing a manic or hypomanic episode
  • Patients experiencing a major depressive episode
  • Patients participating in an interventional study involving a drug or medical device or a Category 1 RIPH within 3 months prior to inclusion
  • Pregnant, parturient, or breastfeeding woman
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients with addiction and trauma issues

    Other: ECCCLORE program

Interventions

  • OtherECCCLORE program

    2-hour sessions in groups of up to 10 people, once a week for 12 weeks plus 30-minute individual sessions after each group session At the beginning of each session, there will be a discussion about the past week and home practices. This will be followed by an alternation between presentations/explanations of key concepts and associated practices. In the individual sessions the previous session and any difficulties encountered during the group session will be reviewed, as well as to address the implementation of home practices.

06

What researchers measure

Primary outcomes

  1. Feasibility of a shortened 12-week ECCCLORE program for patients with addiction and trauma issues

    Percentage of participants who attended 8 or more sessions

    Time frame: Week 12

  2. Dropout rate of a shortened 12-week ECCCLORE program for patients with addiction and trauma issues.

    Percentage of participants missing 5 or more sessions

    Time frame: Week 12

  3. Acceptability of the home practice section of the ECCCLORE program

    Percentage of participants completing the exercises 8 or more times out of 12 sessions

    Time frame: Week 12

Secondary outcomes

  1. Patient-reported trauma

    International Trauma Questionnaire (ITQ), where PTSD requires the presence of at least one symptom in each of the three symptom clusters plus at least one indicator of functional impairment corresponding to a score ≥ 2 on one item. CPTSD further requires confirmation of at least one symptom in each cluster of disturbance in self-organization and associated functional impairment.

    Time frame: Baseline

  2. Patient-reported trauma

    International Trauma Questionnaire (ITQ), where PTSD requires the presence of at least one symptom in each of the three symptom clusters plus at least one indicator of functional impairment corresponding to a score ≥ 2 on one item. CPTSD further requires confirmation of at least one symptom in each cluster of disturbance in self-organization and associated functional impairment.

    Time frame: Week 12

  3. Patient-reported trauma

    International Trauma Questionnaire (ITQ), where PTSD requires the presence of at least one symptom in each of the three symptom clusters plus at least one indicator of functional impairment corresponding to a score ≥ 2 on one item. CPTSD further requires confirmation of at least one symptom in each cluster of disturbance in self-organization and associated functional impairment.

    Time frame: Week 24

  4. Patient-reported addiction

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), for alcohol a score 0-10 is classed as low risk, 11-26: moderate risk, 27 or more: high risk and for other substances: 0-3: low risk, 4-26: moderate risk, 27 or more: high risk.

    Time frame: Baseline

  5. Patient-reported addiction

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), for alcohol a score 0-10 is classed as low risk, 11-26: moderate risk, 27 or more: high risk and for other substances: 0-3: low risk, 4-26: moderate risk, 27 or more: high risk.

    Time frame: Week 12

  6. Patient-reported addiction

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), for alcohol a score 0-10 is classed as low risk, 11-26: moderate risk, 27 or more: high risk and for other substances: 0-3: low risk, 4-26: moderate risk, 27 or more: high risk.

    Time frame: Week 24

  7. Patient-reported impulsivity

    UPPS-P questionnaire used to measure positive urgency, negative urgency, lack of premeditation, lack of perseverance and sensation seeking

    Time frame: Baseline

  8. Patient-reported impulsivity

    UPPS-P questionnaire used to measure positive urgency, negative urgency, lack of premeditation, lack of perseverance and sensation seeking

    Time frame: Week 12

  9. Patient-reported impulsivity

    UPPS-P questionnaire used to measure positive urgency, negative urgency, lack of premeditation, lack of perseverance and sensation seeking

    Time frame: Week 24

  10. Hostile Attribution Bias

    Word Sentence Association Paradigm-Hostility (WSAP-H), in which hostile attribution biases are calculated by averaging the scores across the 16 trials with a hostile word. The higher the score, the greater the hostile attribution bias.

    Time frame: Baseline

  11. Hostile Attribution Bias

    Word Sentence Association Paradigm-Hostility (WSAP-H), in which hostile attribution biases are calculated by averaging the scores across the 16 trials with a hostile word. The higher the score, the greater the hostile attribution bias.

    Time frame: Week 12

  12. Hostile Attribution Bias

    Word Sentence Association Paradigm-Hostility (WSAP-H), in which hostile attribution biases are calculated by averaging the scores across the 16 trials with a hostile word. The higher the score, the greater the hostile attribution bias.

    Time frame: Week 24

  13. Patient-reported aggressivity

    Aggression Questionnaire (AQ-12). Items are rated using a 6-point Likert-type scale ranging from 1 "does not apply to me at all" to 6 "applies to me completely".

    Time frame: Baseline

  14. Patient-reported aggressivity

    Aggression Questionnaire (AQ-12). Items are rated using a 6-point Likert-type scale ranging from 1 "does not apply to me at all" to 6 "applies to me completely".

    Time frame: Week 12

  15. Patient-reported aggressivity

    Aggression Questionnaire (AQ-12). Items are rated using a 6-point Likert-type scale ranging from 1 "does not apply to me at all" to 6 "applies to me completely".

    Time frame: Week 24

  16. Patient-reported flexibility

    Multidimensional Psychological Flexibility Inventory Short-Form (MPFI-24), only items 1 to 12 will be tested: acceptance, awareness of the present moment, defusion, self as context, contact with values, and committed actions.

    Time frame: Baseline

  17. Patient-reported flexibility

    Multidimensional Psychological Flexibility Inventory Short-Form (MPFI-24), only items 1 to 12 will be tested: acceptance, awareness of the present moment, defusion, self as context, contact with values, and committed actions.

    Time frame: Week 12

  18. Patient-reported flexibility

    Multidimensional Psychological Flexibility Inventory Short-Form (MPFI-24), only items 1 to 12 will be tested: acceptance, awareness of the present moment, defusion, self as context, contact with values, and committed actions.

    Time frame: Week 24

  19. Patient-reported depression

    Beck Depression Inventory (BDI-21)

    Time frame: Baseline

  20. Patient-reported depression

    Beck Depression Inventory (BDI-21)

    Time frame: Week 12

  21. Patient-reported depression

    Beck Depression Inventory (BDI-21)

    Time frame: Week 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 17 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Sep 26, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07193914
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Oct 31, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Laure Thebault
Contact
laure.thebault@chu-nimes.fr
06.80.13.54.39
Laure Thebault
principal investigator · CHU de Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion